Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome

European Journal of Clinical Pharmacology

Volumn 56, Issue 3, 2000, Pages 231-240

  O'Neil, W M ^a   Gilfix, B M ^a   Markoglou, N ^a   Di Girolamo, A ^b   Tsoukas, C M ^a   Wainer, I W ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CYP2D6; Genotype; HIV AIDS

Indexed keywords

CYTOCHROME P450; DEXTROMETHORPHAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GENE ACTIVITY; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLISM; PHENOTYPE; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HIV SEROPOSITIVITY; HUMANS; LIPOPOLYSACCHARIDES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHENOTYPE;

EID: 0033920865     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000116     Document Type: Article

References (58)

1. 1. Gonzalez FJ, Idle JR (1994) Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokinet 26: 59-70
2. 2. Daly AK, Cholerton S, Gregory W, Idle JR (1993) Metabolic polymorphisms. Pharmacol Ther 57: 129-160
3. 3. Kaufmann GR, Wenk M, Taeschner W, Peterli B, Gyr K, Meyer UA, Haefeli WE (1996) N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 60: 62-67
4. 4. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ (1996) The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60: 522-534
5. 5. Correia MA (1995) Drug biotransformation. In: Katzung BG (ed) Basic and clinical pharmacology. Appleton and Lange, Norwalk, pp 48-59
6. 6. Parke DV, Ioannides C (1981) The role of nutrition in toxicology. Annu Rev Nutr 1: 207-234
7. 7. O'Neil W, Gilfix BM, DiGirolamo A, Tsoukas CM, Wainer IW (1997) N-acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow? Clin Pharmacol Ther 62: 261-271
8. 8. Lee BL, Wong D, Benowitz NL, Sullam PM (1993) Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 53: 529-535
9. 9. Deloménie C, Grant DM, Mathelier-Fusade P, Jacomet C, Leynadier F, Jacqz-Aigrain E, Rozenbaum W, Krishnamoorthy R, Dupret JM (1994) N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients. Br J Clin Pharmacol 38: 581-582
10. 10. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183-187
11. 11. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjoqvist F (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51: 388-397
12. 12. Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38: 618-624
13. 13. Brøsen K, Gram LF (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36: 537-547
14. 14. Jones DR, Gorski JC, Hamman MA, Hall SD (1996) Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chromatogr B Biomed Appl 678: 105-111
15. 15. Ducharme J, Abdullah S, Wainer IW (1996) Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 678: 113-128
16. 16. Bock KW, Schrenk D, Forster A, Griese EU, Morike K, Brockmeier D, Eichelbaum M (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4: 209-218
17. 17. Jacqz E, Dulac H, Mathieu H (1988) Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 35: 167-171
18. 18. Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE (1991) Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 50: 308-313
19. 19. Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 46: 377-394
20. 20. Meyer UA, Skoda RC, Zanger UM (1990) The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. Pharmacol Ther 46: 297-308
21. 21. Dahl ML, Iselius L, Alm C, Svensson JO, Lee D, Johansson I, Ingelman-Sundberg M, Sjoqvist F (1993) Polymorphic 2-hydroxylation of desipramine. A population and family study. Eur J Clin Pharmacol 44: 445-450
22. 22. Brøsen K, Zeugin T, Meyer UA (1991) Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 49: 609-617
23. 23. Llerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L (1992) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14: 92-97
24. 24. Yue QY, Svensson JO, Alm C, Sjoqvist F, Sawe J (1989) Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol 28: 639-645
25. 25. Stevens JC, Wrighton SA (1993) Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exper Ther 266: 964-971
26. 26. Kumar GN, Rodrigues AD, Buko AM, Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exper Ther 277: 423-431
27. 27. Hamelin BA, Turgeon J, Vallee F, Belanger PM, Paquet F, LeBel M (1996) The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 60: 512-521
28. 28. Park YH, Kullberg MP, Hinsvark ON (1984) Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography. J Pharm Sci 73: 24-29
29. 29. Douglas AM, Atchison BA, Somogyi AA, Drummer OH (1994) Interpretation of a simple PCR analysis of the CY-P2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism. Pharmacogenetics 4: 154-158
30. 30. Daly AK, Steward A (1995) Use of the Expand long template PCR system in genotyping for polymorphisms in the human cytochrome P450 2D6 gene. Boehringer Mannheim Biochemica 4: 31-32
31. 31. Kupfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: 753-759
32. 32. Prevention CfDCa (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR CDC Surveill Summ 41: 1-19
33. 33. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60: 284-295
34. 34. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6: 193-201
35. 35. Bosso JA, Lia Q, Evans WE, Relling MV (1996) CYP2D6, N-acetylation, and xanthine oxidase activity in cystic fibrosis. Pharmacotherapy 16: 749-753
36. 36. Straka RJ, Hansen SR, Walker PF (1995) Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota. Clin Pharmacol Ther 58: 29-34
37. 37. Anthony LB, Boeve TJ, Hande KR (1995) Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes. Cancer Chemother Pharmacol 36: 125-128
38. 38. Hou ZY, Chen CP, Yang WC, Lai MD, Buchert ET, Chung HM, Pickle LW, Woosley RL (1996) Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis. Clin Pharmacol Ther 59: 411-417
39. 39. Sindrup S, Brøsen K, Gram L, Hallas J, Skjelbo E, Allen A, Allen G, Cooper S, Mellows G, Tasker T, et al (1992) The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51: 278-287
40. 40. Nielsen K, Brøsen K, Gram L (1992) Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/ debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 43: 405-411
41. 41. Funck-Brentano C, Thomas G, Jacqz-Aigrain E, Poirier JM, Simon T, Bereziat G, Jaillon P (1992) Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exper Ther 263: 780-786
42. 42. Williams ML, Bhargava P, Cherrouk I, Marshall JL, Flockhart DA, Wainer IW (2000) A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. Br J Clin Pharmacol (in press)
43. 43. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR (1992) Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74: 1045-1052
44. 44. Rautonen J, Rautonen N, Martin NL, Philip R, Wara DW (1991) Serum interleukin-6 concentrations are elevated and associated with elevated tumor necrosis factor-alpha and immunoglobulin G and A concentrations in children with HIV infection. AIDS 5: 1319-1325
45. 45. Ayehunie S, Sonnerborg A, Yemane-Berhan T, Zewdie DW, Britton S, Strannegard O (1993) Raised levels of tumour necrosis factor-alpha and neopterin, but not interferon-alpha, in serum of HIV-1-infected patients from Ethiopia. Clin Exp Immunol 91: 37-42
46. 46. Chollet-Martin S, Simon F, Matheron S, Joseph CA, Elbim C, Gougerot-Pocidalo MA (1994) Comparison of plasma cytokine levels in African patients with HIV-1 and HIV-2 infection. AIDS 8: 879-884
47. 47. Lahdevirta J, Maury CP, Teppo AM, Repo H (1988) Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 85: 289-291
48. 48. Cox RA, Anders GT, Cappelli PJ, Johnson JE, Blanton HM, Seaworth BJ, Treasure RL (1990) Production of tumor necrosis factor-alpha and interleukin-1 by alveolar macrophages from HIV-1-infected persons. AIDS Res Hum Retroviruses 6: 431-441
49. 49. Breen EC, Rezai AR, Nakajima K, Beall GN, Mitsuyasu RT, Hirano T, Kishimoto T, Martinez-Maza O (1990) Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 144: 480-484
50. 50. Molina JM, Schindler R, Ferriani R, Sakaguchi M, Vannier E, Dinarello CA, Groopman JE (1990) Production of cytokines by peripheral blood monocytes/macrophages infected with human immunodeficiency virus type 1 (HIV-1). J Infect Dis 161: 888-893
51. 51. Mildvan D, Machado SG, Wilets I, Grossberg SE (1992) Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 339: 453-456
52. 52. Ghezzi P, Saccardo B, Villa P, Rossi V, Bianchi M, Dinarello CA (1986) Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infect Immun 54: 837-840
53. 53. Shedlofsky SI, Swim AT, Robinson JM, Gallicchio VS, Cohen DA, McClain CJ (1987) Interleukin-1 (IL-1) depresses cytochrome P450 levels and activities in mice. Life Sci 40: 2331-2336
54. s 54. Kurokohchi K, Yoneyama H, Matsuo Y, Nishioka M, Ichikawa Y (1992) Effects of interleukin 1 alpha on the activities and gene expressions of the cytochrome P450IID subfamily. Biochem Pharmacol 44: 1669-1674
55. 55. Shedlofsky SI, Israel BC, McClain CJ, Hill DB, Blouin RA (1994) Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 94: 2209-2214
56. 56. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP (1989) Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28: 4993-4999
57. 57. Ha HR, Chen J, Freiburghaus AU, Follath F (1995) Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 39: 321-326
58. 58. Tseng AL, Foisy MM (1997) Management of drug interactions in patients with HIV. Ann Pharmacother 31: 1040-1058